287 related articles for article (PubMed ID: 33959012)
1. Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling.
Paraiso IL; Tran TQ; Magana AA; Kundu P; Choi J; Maier CS; Bobe G; Raber J; Kioussi C; Stevens JF
Front Pharmacol; 2021; 12():643857. PubMed ID: 33959012
[TBL] [Abstract][Full Text] [Related]
2. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
3. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity.
Guo GL; Lambert G; Negishi M; Ward JM; Brewer HB; Kliewer SA; Gonzalez FJ; Sinal CJ
J Biol Chem; 2003 Nov; 278(46):45062-71. PubMed ID: 12923173
[TBL] [Abstract][Full Text] [Related]
4. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
[TBL] [Abstract][Full Text] [Related]
6. Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice.
Fuchs CD; Krivanec S; Steinacher D; Mlitz V; Wahlström A; Stahlman M; Claudel T; Scharnagl H; Stojakovic T; Marschall HU; Trauner M
Liver Int; 2020 Jun; 40(6):1366-1377. PubMed ID: 32141703
[TBL] [Abstract][Full Text] [Related]
7. Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation.
Sheng L; Jena PK; Liu HX; Kalanetra KM; Gonzalez FJ; French SW; Krishnan VV; Mills DA; Wan YY
Sci Rep; 2017 May; 7(1):1748. PubMed ID: 28496104
[TBL] [Abstract][Full Text] [Related]
8. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
[TBL] [Abstract][Full Text] [Related]
9. Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet.
Okushin K; Tsutsumi T; Ikeuchi K; Kado A; Enooku K; Fujinaga H; Yamauchi N; Ushiku T; Moriya K; Yotsuyanagi H; Koike K
PLoS One; 2020; 15(8):e0234750. PubMed ID: 32785220
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism.
Zhang L; Xie C; Nichols RG; Chan SH; Jiang C; Hao R; Smith PB; Cai J; Simons MN; Hatzakis E; Maranas CD; Gonzalez FJ; Patterson AD
mSystems; 2016; 1(5):. PubMed ID: 27822554
[TBL] [Abstract][Full Text] [Related]
11. Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis.
Liu X; Wang J; Li M; Qiu J; Li X; Qi L; Liu J; Liu P; Xie G; Wang X
J Gastroenterol Hepatol; 2023 Aug; 38(8):1438-1446. PubMed ID: 37415275
[TBL] [Abstract][Full Text] [Related]
12. Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor.
Tveter KM; Villa-Rodriguez JA; Cabales AJ; Zhang L; Bawagan FG; Duran RM; Roopchand DE
BMJ Open Diabetes Res Care; 2020 Aug; 8(1):. PubMed ID: 32771984
[TBL] [Abstract][Full Text] [Related]
13. Xanthohumol improves cognition in farnesoid X receptor-deficient mice on a high-fat diet.
Kundu P; Paraiso IL; Choi J; Miranda CL; Kioussi C; Maier CS; Bobe G; Stevens JF; Raber J
Dis Model Mech; 2022 Nov; 15(11):. PubMed ID: 36353888
[TBL] [Abstract][Full Text] [Related]
14. Lactoferrin promotes bile acid metabolism and reduces hepatic cholesterol deposition by inhibiting the farnesoid X receptor (FXR)-mediated enterohepatic axis.
Ling CJ; Xu JY; Li YH; Tong X; Yang HH; Yang J; Yuan LX; Qin LQ
Food Funct; 2019 Nov; 10(11):7299-7307. PubMed ID: 31626262
[TBL] [Abstract][Full Text] [Related]
15. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice.
Gu M; Zhao P; Zhang S; Fan S; Yang L; Tong Q; Ji G; Huang C
Br J Pharmacol; 2019 Apr; 176(7):847-863. PubMed ID: 30635917
[TBL] [Abstract][Full Text] [Related]
16. Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis
Li H; Xi Y; Liu H; Xin X
Front Nutr; 2022; 9():914079. PubMed ID: 36091227
[TBL] [Abstract][Full Text] [Related]
17. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.
Wu WB; Chen YY; Zhu B; Peng XM; Zhang SW; Zhou ML
Biochimie; 2015 Aug; 115():86-92. PubMed ID: 26025474
[TBL] [Abstract][Full Text] [Related]
18. Myclobutanil-mediated alteration of liver-gut FXR signaling in mice.
Taylor R; Armstrong L; Bhattacharya A; Henry Z; Brinker A; Buckley B; Kong B; Guo G
Toxicol Sci; 2023 Feb; 191(2):387-399. PubMed ID: 36511616
[TBL] [Abstract][Full Text] [Related]
19. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
[TBL] [Abstract][Full Text] [Related]
20. Bile Diversion Improves Metabolic Phenotype Dependent on Farnesoid X Receptor (FXR).
Pierre JF; Li Y; Gomes CK; Rao P; Chang EB; Yin DP
Obesity (Silver Spring); 2019 May; 27(5):803-812. PubMed ID: 30933435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
